HOME Top Market Reports Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecasts to 2021

By: marketsandmarkets.com
Publishing Date: January 2017
Report Code: MD 3687

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The global blood screening market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%. The global market is broadly classified into technology, product & service, end user, and region.

On the basis of technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. The NAT segment is further subsegmented into transcription-mediated amplification (TMA) and real-time PCR. The ELISA segment is further classified based on various platforms and generations. On the basis of platform, the ELISA market is segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). On the basis of generation, the ELISA market is segmented into first generation ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA.

On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is further subsegmented into NAT reagents and kits, ELISA reagents and kits, and other reagents and kits. On the basis of purchase mode, the instruments market is segmented into rental purchase and outright purchase.

Based on end user, the blood screening market is segmented into blood banks and hospitals.

Based on region, the market is segmented into North America, Europe, Asia, and RoW.

The major players in the blood screening market are Grifols (Spain), Bio-Rad Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMιrieux (France), Abbott Laboratories (U.S.), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), and Becton, Dickinson and Company (U.S).

Target Audience for this Report:

  • Blood Screening Instruments and Reagents Manufacturers
  • Blood Screening Software and Services Providers
  • Blood Banks
  • Hospitals
  • Red Cross Societies
  • Regulatory Bodies
  • Research and Consulting Firms
  • Government Bodies

Value Addition for the Buyer:

This report aims to provide insights into the global blood screening market. It provides valuable information on the technology, product & service, end user, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

The abovementioned information would benefit the buyer by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize the growth opportunities.

Scope of the Report:

This report categorizes the blood screening market into the following segments:

Global Blood Screening Market, by Technology

  • Nucleic Acid Test (NAT)
    • Transcription-mediated Amplification (TMA)
    • Real-time Polymerase Chain Reaction (PCR)
  • Enzyme-linked Immunosorbent Assay (ELISA)
    • By Platform
      • Chemiluminescence Immunoassay (CLIA)
      • Fluorescence Immunoassay (FIA)
      • Colorimetric Immunoassay (CI)
    • By Generation
      • First Generation
      • Second Generation
      • Third Generation
      • Fourth Generation & Above
  • Rapid Tests
  • Western Blot Assay
  • Next-generation Sequencing (NGS)

Global Blood Screening Market, by Product & Service

  • Reagents & Kits
    • NAT Reagents & Kits
  • Enzymes and Polymerases
  • Standards and Controls
  • Probes and Primers
  • Buffers, Nucleotides, and Solutions
  • Labeling and Detection Reagents
    • ELISA Reagents & Kits
  • Immunosorbents
  • Controls
  • Conjugates
  • Substrates
  • Sample Diluents and Wash Solutions
    • Other Reagents & Kits
  • Instruments
    • Rental Purchase
    • Outright Purchase
  • Software and Services

Global Blood Screening Market, by End User

  • Blood Banks
  • Hospitals

Global Blood Screening Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • RoE
  • Asia
    • Japan
    • China
    • India
    • RoA
  • RoW

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Secondary Data
           2.1.1 Key Data From Secondary Sources
    2.2 Primary Data
           2.2.1 Key Data From Primary Sources
    2.3 Market Size Estimation
           2.3.1 Bottom-Up Approach
           2.3.2 Top-Down Approach
    2.4 Market Breakdown & Data Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 24)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Conclusion

4 Premium Insights (Page No. - 29)
    4.1 Blood Screening Market
    4.2 Blood Screening Market, By Region & Technology

5 Market Overview (Page No. - 31)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Number of Blood Donations and Blood Donors
                    5.2.1.2 Increasing Demand of Donated Blood
                    5.2.1.3 Rising Prevalence of Infectious Diseases
                    5.2.1.4 Growing Affordability and Adoption of NAT for Blood Screening
                    5.2.1.5 Rising Awareness Regarding the Safety of Donated Blood
           5.2.2 Restraints
                    5.2.2.1 Capital Expenditure and Operating Costs of NAT
                    5.2.2.2 Lack of Regulations Mandating the Use of NAT in Developing Countries
                    5.2.2.3 Emergence of Alternative Technologies
           5.2.3 Opportunities
                    5.2.3.1 Pathogen Reduction Technology
                    5.2.3.2 Multiplex Tests
                    5.2.3.3 Emerging Economies
           5.2.4 Challenges
                    5.2.4.1 Price Reduction

6 Blood Screening Market, By Technology (Page No. - 38)
    6.1 Introduction
    6.2 Blood Screening Market, By Volume (Number of Tests Conducted)
    6.3 Nucleic Acid Test (NAT)
           6.3.1 Transcription-Mediated Amplification (TMA)
           6.3.2 Real-Time Polymerase Chain Reaction (PCR)
    6.4 Enzyme-Linked Immunosorbent Assay (ELISA)
           6.4.1 ELISA Market, By Platform
                    6.4.1.1 Chemiluminescence Immunoassay (CLIA)
                    6.4.1.2 Fluorescence Immunoassay (FIA)
                    6.4.1.3 Colorimetric Immunoassay (CI)
           6.4.2 ELISA Market, By Generation
                    6.4.2.1 First-Generation ELISA
                    6.4.2.2 Second-Generation ELISA
                    6.4.2.3 Third-Generation ELISA
                    6.4.2.4 Fourth-Generation & Above
    6.5 Rapid Tests
    6.6 Western Blot Assay
    6.7 Next-Generation Sequencing (NGS)

7 Blood Screening Market, By Product and Service (Page No. - 56)
    7.1 Introduction
    7.2 Reagents & Kits
           7.2.1 NAT Reagents & Kits
                    7.2.1.1 Enzymes and Polymerases
                    7.2.1.2 Standards and Controls
                    7.2.1.3 Probes and Primers
                    7.2.1.4 Buffers, Nucleotides and Solutions
                    7.2.1.5 Labeling and Detection Reagents
           7.2.2 ELISA Reagents & Kits
                    7.2.2.1 Immunosorbents
                    7.2.2.2 Controls
                    7.2.2.3 Conjugates (Antigen Or Antibody-Conjugated Enzyme)
                    7.2.2.4 Substrates (Of Enzymes)
                    7.2.2.5 Sample Diluents and Wash Solutions
           7.2.3 Other Reagents
    7.3 Instruments
           7.3.1 Rental Purchase
           7.3.2 Outright Purchase
    7.4 Software and Services

8 Blood Screening Market, By End User (Page No. - 68)
    8.1 Introduction
    8.2 Blood Banks
    8.3 Hospitals

9 Blood Screening Market, By Region (Page No. - 72)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 France
           9.3.3 U.K.
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 Rest of Europe (RoE)
    9.4 Asia
           9.4.1 Japan
           9.4.2 China
           9.4.3 India
           9.4.4 Rest of Asia (RoA)
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 104)
     10.1 Overview
     10.2 Market Share Analysis
             10.2.1 Market Share Analysis for NAT
             10.2.2 Blood Screening Market Share Analysis
     10.3 Competitive Situations and Trends
             10.3.1 Product Launches
             10.3.2 Regulatory Approvals
             10.3.3 Agreements
             10.3.4 Partnerships
             10.3.5 Acquisitions
             10.3.6 Expansions

11 Company Profiles (Page No. - 113)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     11.1 Introduction
     11.2 Grifols
     11.3 F. Hoffmann-La Roche
     11.4 Abbott Laboratories
     11.5 Biomιrieux
     11.6 Bio-Rad Laboratories, Inc.
     11.7 Siemens Healthineers (A Subsidiary of Siemens AG)
     11.8 Ortho Clinical Diagnostics, Inc.
     11.9 Thermo Fisher Scientific, Inc.
     11.10 Beckman Coulter (A Subsidiary of Danaher Corporation)
     11.11 Becton, Dickinson and Company

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 139)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Introducing RT: Real-Time Market Intelligence
     12.4 Available Customizations
     12.5 Related Reports
     12.6 Author Details


List of Tables (97 Tables)

Table 1 Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 2 Global Market, By Volume (Number of Tests), 2015
Table 3 North America: Market, By Volume (Number of Tests), 2015
Table 4 Europe: Market, By Volume (Number of Tests), 2015
Table 5 Asia: Market, By Volume (Number of Tests), 2015
Table 6 Market Size for NAT, By Country, 2014–2021 (USD Million)
Table 7 Market Size for NAT, By Type, 2014–2021 (USD Million)
Table 8 TMA Market Size, By Country, 2014–2021 (USD Million)
Table 9 Real-Time PCR Market Size, By Country, 2014–2021 (USD Million)
Table 10 Market Size for ELISA, By Country, 2014–2021 (USD Million)
Table 11 Market Size for ELISA, By Platform, 2014–2021 (USD Million)
Table 12 CLIA Market Size, By Country, 2014–2021 (USD Million)
Table 13 FIA Market Size, By Country, 2014–2021 (USD Million)
Table 14 CI Market Size, By Country, 2014–2021 (USD Million)
Table 15 Market Size for ELISA, By Generation, 2014-2021 (USD Million)
Table 16 First-Generation ELISA Market Size, By Country, 2014–2021 (USD Million)
Table 17 Second-Generation ELISA Market Size, By Country, 2014–2021 (USD Million)
Table 18 Third-Generation ELISA Market Size, By Country, 2014–2021 (USD Million)
Table 19 Fourth-Generation ELISA Market Size, By Country, 2014–2021 (USD Million)
Table 20 Market Size for Rapid Tests, By Country, 2014–2021 (USD Million)
Table 21 Market Size for Western Blot Assay, By Country, 2014–2021 (USD Million)
Table 22 Market Size for NGS, By Country, 2014–2021 (USD Million)
Table 23 Market Size, By Product and Service, 2014–2021 (USD Million)
Table 24 Blood Screening Reagents and Kits Market Size, By Country, 2014–2021 (USD Million)
Table 25 Blood Screening Reagents and Kits Market Size, By Type, 2014–2021 (USD Million)
Table 26 NAT Reagents & Kits Market Size, By Country, 2014–2021 (USD Million)
Table 27 NAT Reagents & Kits Market Size, By Type, 2014–2021 (USD Million)
Table 28 ELISA Reagents & Kits Market Size, By Country, 2014–2021 (USD Million)
Table 29 ELISA Reagents & Kits Market Size, By Type, 2014–2021 (USD Million)
Table 30 Other Reagents & Kits Market Size, By Country, 2014–2021 (USD Million)
Table 31 Blood Screening Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 32 Blood Screening Instruments Market Size, By Purchase Mode, 2014–2021 (USD Million)
Table 33 Rental Purchase Market Size, By Country, 2014–2021 (USD Million)
Table 34 Outright Purchase Market Size, By Country, 2014–2021 (USD Million)
Table 35 Blood Screening Software and Services Market Size, By Country, 2014–2021 (USD Million)
Table 36 Market Size, By End User, 2014–2021 (USD Million)
Table 37 Market Size for Blood Banks, By Country, 2014–2021 (USD Million)
Table 38 Market Size for Hospitals, By Country, 2014–2021 (USD Million)
Table 39 Global Market Size, By Region, 2012–2019 (USD Million)
Table 40 North America: Market Size, By Country, 2014-2021 (USD Million)
Table 41 North America: Market Size, By Technology, 2014-2021 (USD Million)
Table 42 North America: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 43 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 44 Number of Organ Transplantations Performed in the U.S., 2014-2015
Table 45 U.S.: Market Size, By Technology, 2014–2021 (USD Million)
Table 46 U.S.: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 47 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 48 Canada: Market Size, By Technology, 2014–2021 (USD Million)
Table 49 Canada: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 50 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 51 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 52 Europe: Market Size, By Technology, 2014–2021 (USD Million)
Table 53 Europe: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 54 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 55 Germany: Market Size, By Technology, 2014–2021 (USD Million)
Table 56 Germany: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 57 Germany: Market Size, By End User, 2014–2021 (USD Million)
Table 58 France: Market Size, By Technology, 2014–2021 (USD Million)
Table 59 France: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 60 France: Market Size, By End User, 2014–2021 (USD Million)
Table 61 U.K.: Market Size, By Technology, 2014–2021 (USD Million)
Table 62 U.K.: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 63 U.K.: Market Size, By End User, 2014–2021 (USD Million)
Table 64 Italy: Market Size, By Technology, 2014–2021 (USD Million)
Table 65 Italy: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 66 Italy: Market Size, By End User, 2014–2021 (USD Million)
Table 67 Spain: Market Size, By Technology, 2014–2021 (USD Million)
Table 68 Spain: Market Size, By Product and Service, 2014–2021 (USD Million)
Table 69 Spain: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 70 RoE: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 71 RoE: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 72 RoE: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 73 Asia: Blood Screening Market Size, By Country, 2014–2021 (USD Million)
Table 74 Asia: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 75 Asia: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 76 Asia: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 77 Japan: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 78 Japan: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 79 Japan: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 80 China: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 81 China: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 82 China: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 83 India: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 84 India: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 85 India: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 86 RoA: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 87 RoA: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 88 RoA: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 89 RoW: Blood Screening Market Size, By Technology, 2014–2021 (USD Million)
Table 90 RoW: Blood Screening Market Size, By Product and Service, 2014–2021 (USD Million)
Table 91 RoW: Blood Screening Market Size, By End User, 2014–2021 (USD Million)
Table 92 Product Launches, 2013-2016
Table 93 Regulatory Approvals, 2013–2016
Table 94 Agreements, 2013–2016
Table 95 Partnerships, 2013–2016
Table 96 Acquisitions, 2013–2016
Table 97 Expansions, 2013–2016


List of Figures (39 Figures)

Figure 1 Research Design
Figure 2 Blood Screening Market: Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation Methodology
Figure 5 Blood Screening Market Size, By Product and Service, 2016 vs 2021 (USD Billion)
Figure 6 Blood Screening Market Size, By Technology, 2016 vs 2021 (USD Billion)
Figure 7 Blood Screening Market Size, By End User, 2016 vs 2021 (USD Billion)
Figure 8 North America Accounted for the Highest Share of the Blood Screening Market in 2016
Figure 9 Blood Screening Market to Showcase Lucrative Growth Opportunities in the Forecast Period
Figure 10 NAT Segment to Account for the Largest Market Share in 2016
Figure 11 Asia to Grow at the Highest Rate During the Forecast Period
Figure 12 Global Incidences of Cancer
Figure 13 NAT Testing Will Continue to Dominate the Market During the Forecast Period
Figure 14 Reagents & Kits Segment to Hold Largest Share of the Market During the Forecast Period
Figure 15 Blood Banks Segment Will Continue to Dominate the Blood Screening Market During the Forecast Period
Figure 16 Emerging Markets Offer Significant Growth Opportunities
Figure 17 Asian Blood Screening Market Expected to Grow at the Highest CAGR During the Forecast Period
Figure 18 North America: Market Snapshot
Figure 19 Reagents and Kits Segment to Hold Largest Share in the U.S. Market
Figure 20 Europe: Market Snapshot
Figure 21 Germany: Blood Screening Market, By Product and Service
Figure 22 Asia: Blood Screening Market Snapshot
Figure 23 ELISA Segment to Grow at the Highest CAGR in the Japanese Market During 2016–2021
Figure 24 Blood Banks End-User Segment Will Continue to Dominate the Indian Blood Screening Market Till 2021
Figure 25 RoW: Market Snapshot
Figure 26 Product Launches, the Key Strategy Adopted By Leading Players
Figure 27 NAT Blood Screening Market Share Analysis, By Key Player, 2015
Figure 28 Blood Screening Market Share Analysis, By Key Player, 2015
Figure 29 Battle for Market Share: Product Launches, Partnerships and Agreements, the Key Growth Strategies Adopted Between 2014 & 2016
Figure 30 Product Benchmarking of the Top 5 Players
Figure 31 Grifols: Company Snapshot
Figure 32 F. Hoffmann-La Roche Ltd: Company Snapshot
Figure 33 Abbott Laboratories: Company Snapshot
Figure 34 Biomιrieux: Company Snapshot
Figure 35 Bio-Rad Laboratories, Inc.: Company Snapshot
Figure 36 Siemens AG: Company Snapshot
Figure 37 Thermo Fisher Scientific, Inc.: Company Snapshot
Figure 38 Danaher Corporation: Company Snapshot
Figure 39 Becton, Dickinson and Company: Company Snapshot

Blood screening is a medical process in which donated blood is mainly tested for HIV1, HIV2, HBV, HCV, malaria, syphilis, and various other infectious diseases. Donated blood is screened for these infectious diseases to reduce the risk of transfusion-transmitted infections (TTIs).

The global blood screening market consists of various technologies and products & services which are used in blood banks and hospitals for the screening of various TTIs. The market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%.

The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market. However, capital expenditure and the operating costs of NAT instruments, lack of mandates for NAT in developing countries, and the emergence of alternative technologies are restraining market growth. Furthermore, some of the major opportunities observed in this market include growing economies such as China and India, the emergence of pathogen reduction technology, and demand of multiplex tests.

Based on technology, the blood screening market is segmented into NAT, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The NAT segment is further subsegmented into transcription-mediated amplification (TMA) and real-time PCR. The ELISA segment is further categorized into various platforms and generations. On the basis of platform, the ELISA market is segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). On the basis of generation, the ELISA market is segmented into first generation ELISA, second generation ELISA, third generation ELISA, and fourth & above generation ELISA. The NAT segment is expected to dominate the global market in 2016. This growth can be attributed to factors such as increase in blood donation, rising prevalence/incidence of infectious diseases, and increasing capacity (disposable income) to pay for NAT-tested blood.

On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits segment is further divided into NAT reagents and kits, ELISA reagents and kits, and other reagents and kits. On the basis of purchase mode, the instruments market is segmented into rental purchase and outright purchase. In 2016, the reagents and kits segment is expected to account for the largest share of the market.

On the basis of end user, the market is segmented into blood banks and hospitals. In 2016, the blood banks segment is expected to account for the largest share of the global blood screening market. Some of the major factors driving the growth of this segment include increasing demand for donated blood and growing number of organ transplantation surgeries around the world.

Blood Screening Market

The global blood screening market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to witness the highest CAGR during the forecast period, with the growth in this market centred at China, Japan, and India.

The major players in this market include Grifols (Spain), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Roche Diagnostics (Switzerland), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), bioMιrieux (France), and Siemens Healthineers (Germany), and Bio-Rad Laboratories, Inc. (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth In-Vitro Diagnostics Markets on KnowledgeStore
Request Demo